Boston Scientific has shared a range of data highlighting the benefits of spinal cord stimulation (SCS) therapies within its neuromodulation portfolio.
The medtech giant presented a total of 17 abstracts, including seven oral presentations, at this year’s North American Neuromodulation Society (NANS) annual meeting, which took place in Las Vegas between 22-25 January.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Chief among the insights shared were three-year outcomes from Boston’s FAST Global Real-World Study of its Fast-Acting Sub-perception Therapy (FAST), three-year outcomes from the Global RELIEF Registry charting patient outcomes of SCS therapy across multiple indications, and two-year results from the SOLIS trial of non-surgical back pain outcomes for patients using FAST therapy.
FAST therapy is delivered via Boston’s WaveWriter Alpha, an implantable pulse generator (IPG) that stimulates the spinal cord to deliver pain relief from conditions such as paraesthesia. WaveWriter Alpha was US Food and Drug Administration (FDA)-approved in 2020 with a market rollout in the US initiated in January 2021.
Scott Kreiner, Boston’s chief medical officer, told Medical Device Network that the FAST Global Real-World Study demonstrated FAST’s performance in delivering “durable, rapid, paraesthesia-free relief”.
“82% of patients achieved 50% or greater pain relief at three years and low average pain scores sustained long term,” Kreiner said.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn the SOLIS randomised control trial of FAST, nearly nine in 10 patients experienced significant pain relief at two years, alongside large, sustained improvements in daily function, according to Boston.
Meanwhile, in the Global RELIEF Registry, which featured more than 500 SCS patients across multiple chronic pain conditions, 74% maintained 50% or greater pain relief at three years, with similarly strong results across all indications and high patient-reported improvement, Boston said.
Kreiner concluded: “Together, these data show that Boston Scientific’s SCS therapies can provide fast, meaningful, and long-lasting pain relief across a broad range of chronic pain conditions, helping patients reduce pain and restore function and quality of life for years.”
Boston advancing neuromodulation product offerings
Boston’s recent strong financial performance has largely been driven by its cardiovascular portfolio due to the ongoing market adoption of its Farapulse Pulsed-Field Ablation (PFA) system for atrial fibrillation (AFib) treatment. However, recent actions from Boston suggest there is a growing drive towards advancing its neuromodulation product offerings.
In Q3 2025, the neuromodulation segment within Boston’s MedSurg portfolio grew by 9.1% versus Q3 2024 to $293m.
To complement Boston’s existing pain management therapies such as WaveWriter, the company acquired Nalu Medical in a $533m deal in October 2025. The California-based company’s lead product, the Nalu Neurostimulation System, is designed to address chronic pain in regions such as the shoulder, lower back and knee via peripheral nerve stimulation (PNS).
Boston also announced an agreement to acquire Valencia Technologies for an undisclosed sum at this year’s J.P. Morgan Healthcare Conference. While Valencia’s implantable tibial nerve stimulation (ITNS) treatment will tuck into Boston’s urology portfolio, the move suggests the company’s general ambition to strengthen its product lines with further neuromodulation technologies.
According to GlobalData analysis, the global neurology devices market is projected to reach a valuation above $25bn in 2034.
